Kimura T, Iwamiya M, Yoshida N, Iwamoto A, Sasada M, Ito S, Kikuchi N, Kimoto S
Department of Clinical Pathology and Clinical Laboratories, Kanagawa Dental College.
Kanagawa Shigaku. 1990 Jun;25(1):109-14.
An HB prophylaxis vaccination that included a primary and secondary vaccination was carried out on persons working at the university hospital. In the primary vaccination group, the subjects were inoculated the second time with a vaccine derived from human blood plasma obtained from the Kitazato Therapeutic Research Institute. The third time, they were inoculated with a vaccine from the Chemo-Sero Therapeutic Research Institute derived from a second-generation vaccine organized ferment. The vaccine used for the second inoculation group was obtained from the Chemo-Sero Therapeutic Research Institute. Results were summarized as follows: 1) The primary vaccination group: (1) The number of the 153 subjects inoculated with the primary vaccination at the time of the second inoculation, 49 subjects (32%) tested positive for antibodies 3-4 months following inoculation. Thirty-two subjects (20%) tested positive 15-16 months following inoculation with a high rate among females. (2) Among 104 subjects inoculated the third time with the primary vaccination (those who tested negative the second inoculation of the above vaccine), 61 subjects (58.7%) tested positive for antibodies 8-9 months following inoculation with a generally high rate among females. Twenty-eight subjects (26%) tested 15-16 months after inoculation with a high rate among females between 20 and 30 years and among males between 40 and years. 2) The secondary group: Among the 38 subjects who were inoculated the second time with the secondary vaccination, 8 subjects (21%) tested positive for antibodies 5-6 months following inoculation, with a high rate among females in their 20's. 3) The rate of antibodies formation.(ABSTRACT TRUNCATED AT 250 WORDS)
对大学医院工作人员进行了包含初次和二次接种的乙肝预防疫苗接种。在初次接种组中,受试者第二次接种的是来自北里治疗研究所的人血浆衍生疫苗。第三次接种的是来自化学血清疗法研究所的第二代组织发酵衍生疫苗。二次接种组使用的疫苗来自化学血清疗法研究所。结果总结如下:1)初次接种组:(1)153名在第二次接种时进行初次接种的受试者中,49名受试者(32%)在接种后3至4个月抗体检测呈阳性。32名受试者(20%)在接种后15至16个月抗体检测呈阳性,女性中比例较高。(2)在104名第三次进行初次接种的受试者(上述疫苗第二次接种检测为阴性者)中,61名受试者(58.7%)在接种后8至9个月抗体检测呈阳性,女性中比例普遍较高。28名受试者(26%)在接种后15至16个月检测呈阳性,20至30岁女性和40至岁男性中比例较高。2)二次接种组:在38名进行二次接种的受试者中,8名受试者(21%)在接种后5至6个月抗体检测呈阳性,20多岁女性中比例较高。3)抗体形成率。(摘要截断于250字)